Clinical trials for neurofibromatosis type 1-associated plexiform neurofibromas.
\\n\\n
More than half of the publishers listed alongside IntechOpen (18 out of 30) are Social Science and Humanities publishers. IntechOpen is an exception to this as a leader in not only Open Access content but Open Access content across all scientific disciplines, including Physical Sciences, Engineering and Technology, Health Sciences, Life Science, and Social Sciences and Humanities.
\\n\\nOur breakdown of titles published demonstrates this with 47% PET, 31% HS, 18% LS, and 4% SSH books published.
\\n\\n“Even though ItechOpen has shown the potential of sci-tech books using an OA approach,” other publishers “have shown little interest in OA books.”
\\n\\nAdditionally, each book published by IntechOpen contains original content and research findings.
\\n\\nWe are honored to be among such prestigious publishers and we hope to continue to spearhead that growth in our quest to promote Open Access as a true pioneer in OA book publishing.
\\n\\n\\n\\n
\\n"}]',published:!0,mainMedia:null},components:[{type:"htmlEditorComponent",content:'
Simba Information has released its Open Access Book Publishing 2020 - 2024 report and has again identified IntechOpen as the world’s largest Open Access book publisher by title count.
\n\nSimba Information is a leading provider for market intelligence and forecasts in the media and publishing industry. The report, published every year, provides an overview and financial outlook for the global professional e-book publishing market.
\n\nIntechOpen, De Gruyter, and Frontiers are the largest OA book publishers by title count, with IntechOpen coming in at first place with 5,101 OA books published, a good 1,782 titles ahead of the nearest competitor.
\n\nSince the first Open Access Book Publishing report published in 2016, IntechOpen has held the top stop each year.
\n\n\n\nMore than half of the publishers listed alongside IntechOpen (18 out of 30) are Social Science and Humanities publishers. IntechOpen is an exception to this as a leader in not only Open Access content but Open Access content across all scientific disciplines, including Physical Sciences, Engineering and Technology, Health Sciences, Life Science, and Social Sciences and Humanities.
\n\nOur breakdown of titles published demonstrates this with 47% PET, 31% HS, 18% LS, and 4% SSH books published.
\n\n“Even though ItechOpen has shown the potential of sci-tech books using an OA approach,” other publishers “have shown little interest in OA books.”
\n\nAdditionally, each book published by IntechOpen contains original content and research findings.
\n\nWe are honored to be among such prestigious publishers and we hope to continue to spearhead that growth in our quest to promote Open Access as a true pioneer in OA book publishing.
\n\n\n\n
\n'}],latestNews:[{slug:"intechopen-signs-new-contract-with-cepiec-china-for-distribution-of-open-access-books-20210319",title:"IntechOpen Signs New Contract with CEPIEC, China for Distribution of Open Access Books"},{slug:"150-million-downloads-and-counting-20210316",title:"150 Million Downloads and Counting"},{slug:"intechopen-secures-indefinite-content-preservation-with-clockss-20210309",title:"IntechOpen Secures Indefinite Content Preservation with CLOCKSS"},{slug:"intechopen-expands-to-all-global-amazon-channels-with-full-catalog-of-books-20210308",title:"IntechOpen Expands to All Global Amazon Channels with Full Catalog of Books"},{slug:"stanford-university-identifies-top-2-scientists-over-1-000-are-intechopen-authors-and-editors-20210122",title:"Stanford University Identifies Top 2% Scientists, Over 1,000 are IntechOpen Authors and Editors"},{slug:"intechopen-authors-included-in-the-highly-cited-researchers-list-for-2020-20210121",title:"IntechOpen Authors Included in the Highly Cited Researchers List for 2020"},{slug:"intechopen-maintains-position-as-the-world-s-largest-oa-book-publisher-20201218",title:"IntechOpen Maintains Position as the World’s Largest OA Book Publisher"},{slug:"all-intechopen-books-available-on-perlego-20201215",title:"All IntechOpen Books Available on Perlego"}]},book:{item:{type:"book",id:"5170",leadTitle:null,fullTitle:"Green Nanotechnology - Overview and Further Prospects",title:"Green Nanotechnology",subtitle:"Overview and Further Prospects",reviewType:"peer-reviewed",abstract:"This book, Green Nanotechnology - Overview and Further Prospects, is intended to provide an overview and practical examples of the use of nanomaterials in the new scientific challenges of the green nanotechnology world. We aimed to compile information from a diversity of sources into a single volume to give some real examples, extending the concept that green nanotechnology is far from being a scientific conundrum, and instead a real answer to some of the actual problems the whole planet is dealing with.",isbn:"978-953-51-2410-8",printIsbn:"978-953-51-2409-2",pdfIsbn:"978-953-51-4199-0",doi:"10.5772/61432",price:119,priceEur:129,priceUsd:155,slug:"green-nanotechnology-overview-and-further-prospects",numberOfPages:256,isOpenForSubmission:!1,isInWos:1,hash:"e2d4dc551be023ba3525e6126076af90",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",publishedDate:"June 1st 2016",coverURL:"https://cdn.intechopen.com/books/images_new/5170.jpg",numberOfDownloads:20070,numberOfWosCitations:35,numberOfCrossrefCitations:11,numberOfDimensionsCitations:34,hasAltmetrics:1,numberOfTotalCitations:80,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"October 6th 2015",dateEndSecondStepPublish:"October 27th 2015",dateEndThirdStepPublish:"January 31st 2016",dateEndFourthStepPublish:"April 30th 2016",dateEndFifthStepPublish:"May 30th 2016",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,8",editedByType:"Edited by",kuFlag:!1,editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",middleName:null,surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy",profilePictureURL:"https://mts.intechopen.com/storage/users/14764/images/system/14764.jpeg",biography:"Marcelo L. Larramendy, Ph.D., serves as a Professor of Molecular Cell Biology at the School of Natural Sciences and Museum (National University of La Plata, Argentina). He is the appointed Senior Researcher of the National Scientific and Technological Research Council of Argentina and a former member of the Executive Committee of the Latin American Association of Environmental Mutagensis, Teratogenesis and Carcinogenesis. He is the author of more than 450 contributions, including scientific publications, research communications, and conferences worldwide. He is the recipient of several national and international awards. Prof. Larramendy is a regular lecturer at the international A. Hollaender courses organized by the IAEMS and a former guest scientist at NIH (USA) and University of Helsinki (Finland). He is an expert in genetic toxicology and is, or has been, a referee for more than 20 international scientific journals. He was a member of the International Panel of Experts at the International Agency for Research on Cancer (IARC, WHO, Lyon, France) in 2015 for the evaluation of DDT, 2,4-D and Lindane. Presently, Prof. Dr. Larramendy is Head of the Laboratory of Molecular Cytogenetics and Genotoxicology at the UNLP.",institutionString:"National University of La Plata",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"18",institution:{name:"National University of La Plata",institutionURL:null,country:{name:"Argentina"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:{id:"14863",title:"Dr.",name:"Sonia",middleName:null,surname:"Soloneski",slug:"sonia-soloneski",fullName:"Sonia Soloneski",profilePictureURL:"https://mts.intechopen.com/storage/users/14863/images/system/14863.jpg",biography:"Sonia Soloneski has a Ph.D. in Natural Sciences and is an Assistant Professor of Molecular Cell Biology at the School of Natural Sciences and Museum of La Plata, National University of La Plata, Argentina. She is a member of the National Scientific and Technological Research Council (CONICET) of Argentina in the genetic toxicology field, the Latin American Association of Environmental Mutagenesis, Teratogenesis and Carcinogenesis (ALAMCTA), the Argentinean Society of Toxicology (ATA), the Argentinean Society of Genetics (SAG), the Argentinean Society of Biology (SAB), and the Society of Environmental Toxicology and Chemistry (SETAC). She has authored more than 380 contributions in the field, including scientific publications in peer-reviewed journals and research communications. She has served as a review member for more than 30 scientific international journals. She has been a plenary speaker in scientific conferences and a member of scientific committees. She is a specialist in issues related to genetic toxicology, mutagenesis, and ecotoxicology.",institutionString:"National University of La Plata",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"6",institution:{name:"National University of La Plata",institutionURL:null,country:{name:"Argentina"}}},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"851",title:"Green Chemistry",slug:"environmental-sciences-environmental-chemistry-green-chemistry"}],chapters:[{id:"50705",title:"Metal Nanoparticles as Emerging Green Catalysts",doi:"10.5772/63314",slug:"metal-nanoparticles-as-emerging-green-catalysts",totalDownloads:2635,totalCrossrefCites:1,totalDimensionsCites:5,signatures:"Ahmad Alshammari, V. Narayana Kalevaru and Andreas Martin",downloadPdfUrl:"/chapter/pdf-download/50705",previewPdfUrl:"/chapter/pdf-preview/50705",authors:[{id:"178547",title:"Dr.",name:"Ahmad",surname:"Alshammari",slug:"ahmad-alshammari",fullName:"Ahmad Alshammari"},{id:"180753",title:"Dr.",name:"V. Narayana",surname:"Kalevaru",slug:"v.-narayana-kalevaru",fullName:"V. Narayana Kalevaru"},{id:"180804",title:"Dr.",name:"Andreas",surname:"Martin",slug:"andreas-martin",fullName:"Andreas Martin"}],corrections:null},{id:"50132",title:"Recent Highlights in Green Oxidative Chemical Processes Applied to Steroid Chemistry",doi:"10.5772/62381",slug:"recent-highlights-in-green-oxidative-chemical-processes-applied-to-steroid-chemistry",totalDownloads:1874,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Samuel M. Silvestre, M. Manuel C. Silva and Jorge A. R. Salvador",downloadPdfUrl:"/chapter/pdf-download/50132",previewPdfUrl:"/chapter/pdf-preview/50132",authors:[{id:"69976",title:"Prof.",name:"Jorge António Ribeiro",surname:"Salvador",slug:"jorge-antonio-ribeiro-salvador",fullName:"Jorge António Ribeiro Salvador"},{id:"157541",title:"Prof.",name:"Samuel",surname:"Silvestre",slug:"samuel-silvestre",fullName:"Samuel Silvestre"},{id:"185027",title:"Prof.",name:"Maria Manuel Cruz",surname:"Silva",slug:"maria-manuel-cruz-silva",fullName:"Maria Manuel Cruz Silva"}],corrections:null},{id:"49331",title:"Metal Complexes Immobilized on Magnetic Nanoparticles",doi:"10.5772/61585",slug:"metal-complexes-immobilized-on-magnetic-nanoparticles",totalDownloads:1613,totalCrossrefCites:1,totalDimensionsCites:2,signatures:"Seyed Mohsen Sadeghzadeh and Mehdi Mogharabi",downloadPdfUrl:"/chapter/pdf-download/49331",previewPdfUrl:"/chapter/pdf-preview/49331",authors:[{id:"175879",title:"Dr.",name:"Seyed Mohsen",surname:"Sadeghzadeh",slug:"seyed-mohsen-sadeghzadeh",fullName:"Seyed Mohsen Sadeghzadeh"},{id:"191799",title:"Dr.",name:"Mehdi",surname:"Mogharabi",slug:"mehdi-mogharabi",fullName:"Mehdi Mogharabi"}],corrections:null},{id:"50214",title:"TiO2 Nanostructures and Nanocomposites for Sustainable Photocatalytic Water Purification",doi:"10.5772/62620",slug:"tio2-nanostructures-and-nanocomposites-for-sustainable-photocatalytic-water-purification",totalDownloads:1812,totalCrossrefCites:2,totalDimensionsCites:7,signatures:"Giuseppe Cacciato, Massimo Zimbone, Francesco Ruffino and Maria\nGrazia Grimaldi",downloadPdfUrl:"/chapter/pdf-download/50214",previewPdfUrl:"/chapter/pdf-preview/50214",authors:[{id:"178880",title:"Ph.D.",name:"Francesco",surname:"Ruffino",slug:"francesco-ruffino",fullName:"Francesco Ruffino"},{id:"180334",title:"Dr.",name:"Giuseppe",surname:"Cacciato",slug:"giuseppe-cacciato",fullName:"Giuseppe Cacciato"},{id:"180335",title:"Dr.",name:"Massimo",surname:"Zimbone",slug:"massimo-zimbone",fullName:"Massimo Zimbone"},{id:"180336",title:"Prof.",name:"Maria Grazia",surname:"Grimaldi",slug:"maria-grazia-grimaldi",fullName:"Maria Grazia Grimaldi"}],corrections:null},{id:"50074",title:"Nanostructured TiO2 Layers for Photovoltaic and Gas Sensing Applications",doi:"10.5772/62316",slug:"nanostructured-tio2-layers-for-photovoltaic-and-gas-sensing-applications",totalDownloads:1628,totalCrossrefCites:2,totalDimensionsCites:6,signatures:"André Decroly, Arnaud Krumpmann, Marc Debliquy and Driss\nLahem",downloadPdfUrl:"/chapter/pdf-download/50074",previewPdfUrl:"/chapter/pdf-preview/50074",authors:[{id:"108357",title:"Dr.",name:"Marc",surname:"Debliquy",slug:"marc-debliquy",fullName:"Marc Debliquy"},{id:"156323",title:"Dr.",name:"Driss",surname:"Lahem",slug:"driss-lahem",fullName:"Driss Lahem"},{id:"179585",title:"Associate Prof.",name:"André",surname:"Decroly",slug:"andre-decroly",fullName:"André Decroly"},{id:"179653",title:"MSc.",name:"Arnaud",surname:"Krumpmann",slug:"arnaud-krumpmann",fullName:"Arnaud Krumpmann"}],corrections:null},{id:"50069",title:"Anodic Nanostructures for Solar Cell Applications",doi:"10.5772/62396",slug:"anodic-nanostructures-for-solar-cell-applications",totalDownloads:1297,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Jia Lin, Xiaolin Liu, Shu Zhu and Xianfeng Chen",downloadPdfUrl:"/chapter/pdf-download/50069",previewPdfUrl:"/chapter/pdf-preview/50069",authors:[{id:"4180",title:"Professor",name:"Xianfeng",surname:"Chen",slug:"xianfeng-chen",fullName:"Xianfeng Chen"},{id:"180209",title:"Dr.",name:"Jia",surname:"Lin",slug:"jia-lin",fullName:"Jia Lin"},{id:"180210",title:"Dr.",name:"Xiaolin",surname:"Liu",slug:"xiaolin-liu",fullName:"Xiaolin Liu"},{id:"180211",title:"Ms.",name:"Shu",surname:"Zhu",slug:"shu-zhu",fullName:"Shu Zhu"}],corrections:null},{id:"50106",title:"“Green” Quantum Dots: Basics, Green Synthesis, and Nanotechnological Applications",doi:"10.5772/62327",slug:"-green-quantum-dots-basics-green-synthesis-and-nanotechnological-applications",totalDownloads:3063,totalCrossrefCites:5,totalDimensionsCites:11,signatures:"Carlos A. Martínez Bonilla and Vladimir V. Kouznetsov",downloadPdfUrl:"/chapter/pdf-download/50106",previewPdfUrl:"/chapter/pdf-preview/50106",authors:[{id:"105180",title:"Prof.",name:"Vladimir V.",surname:"Kouznetsov",slug:"vladimir-v.-kouznetsov",fullName:"Vladimir V. Kouznetsov"},{id:"179817",title:"M.Sc.",name:"Carlos A.",surname:"Martínez Bonilla",slug:"carlos-a.-martinez-bonilla",fullName:"Carlos A. Martínez Bonilla"}],corrections:null},{id:"50180",title:"Recent Advances in Environment-Friendly Alkyd Nanocomposites Towards “Greener” Coatings",doi:"10.5772/62448",slug:"recent-advances-in-environment-friendly-alkyd-nanocomposites-towards-greener-coatings",totalDownloads:3229,totalCrossrefCites:0,totalDimensionsCites:2,signatures:"Eram Sharmin, Fahmina Zafar, Nahid Nishat and Sharif Ahmad",downloadPdfUrl:"/chapter/pdf-download/50180",previewPdfUrl:"/chapter/pdf-preview/50180",authors:[{id:"89672",title:"Dr.",name:"Fahmina",surname:"Zafar",slug:"fahmina-zafar",fullName:"Fahmina Zafar"},{id:"107375",title:"Dr.",name:"Eram",surname:"Sharmin",slug:"eram-sharmin",fullName:"Eram Sharmin"},{id:"185271",title:"Prof.",name:"Nahid",surname:"Nishat",slug:"nahid-nishat",fullName:"Nahid Nishat"},{id:"191804",title:"Dr.",name:"Sharif",surname:"Ahmad",slug:"sharif-ahmad",fullName:"Sharif Ahmad"}],corrections:null},{id:"50457",title:"Preparation of Cu2ZnSnS/Se4 Thin Films from Oxide Precursors and its Prospect for Other Cu2MSnS4 Thin Films",doi:"10.5772/63049",slug:"preparation-of-cu2znsns-se4-thin-films-from-oxide-precursors-and-its-prospect-for-other-cu2msns4-thi",totalDownloads:1671,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Guilin Chen, Shuiyuan Chen and Zhigao Huang",downloadPdfUrl:"/chapter/pdf-download/50457",previewPdfUrl:"/chapter/pdf-preview/50457",authors:[{id:"180270",title:"Dr.",name:"Guilin",surname:"Chen",slug:"guilin-chen",fullName:"Guilin Chen"},{id:"185021",title:"Prof.",name:"Shuiyuan",surname:"Chen",slug:"shuiyuan-chen",fullName:"Shuiyuan Chen"},{id:"185022",title:"Prof.",name:"Zhigao",surname:"Huang",slug:"zhigao-huang",fullName:"Zhigao Huang"}],corrections:null},{id:"50087",title:"Friccohesity and Tentropy: New Models of Molecular Sciences",doi:"10.5772/62240",slug:"friccohesity-and-tentropy-new-models-of-molecular-sciences",totalDownloads:1248,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"Man Singh",downloadPdfUrl:"/chapter/pdf-download/50087",previewPdfUrl:"/chapter/pdf-preview/50087",authors:[{id:"24553",title:"Prof.",name:"Man",surname:"Singh",slug:"man-singh",fullName:"Man Singh"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},relatedBooks:[{type:"book",id:"923",title:"Herbicides",subtitle:"Theory and Applications",isOpenForSubmission:!1,hash:"54a8eb808c05a5fe01c676e7047d4576",slug:"herbicides-theory-and-applications",bookSignature:"Sonia Soloneski and Marcelo L. Larramendy",coverURL:"https://cdn.intechopen.com/books/images_new/923.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5184",title:"Environmental Health Risk",subtitle:"Hazardous Factors to Living Species",isOpenForSubmission:!1,hash:"aa20266ad595ce73a9396f4ab0f8112e",slug:"environmental-health-risk-hazardous-factors-to-living-species",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/5184.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5179",title:"Organic Fertilizers",subtitle:"From Basic Concepts to Applied Outcomes",isOpenForSubmission:!1,hash:"93748f3bd6a9c0240d71ffd350d624b1",slug:"organic-fertilizers-from-basic-concepts-to-applied-outcomes",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/5179.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4637",title:"Toxicity and Hazard of Agrochemicals",subtitle:null,isOpenForSubmission:!1,hash:"6aff74df1ea32df7f1e20e29c8363ff5",slug:"toxicity-and-hazard-of-agrochemicals",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/4637.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5362",title:"Toxicology",subtitle:"New Aspects to This Scientific Conundrum",isOpenForSubmission:!1,hash:"2061f273c8b3134dffbcb5256969ecab",slug:"toxicology-new-aspects-to-this-scientific-conundrum",bookSignature:"Sonia Soloneski and Marcelo L. Larramendy",coverURL:"https://cdn.intechopen.com/books/images_new/5362.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4606",title:"Emerging Pollutants in the Environment",subtitle:"Current and Further Implications",isOpenForSubmission:!1,hash:"1502287827685f0b71235bd45fe35ae4",slug:"emerging-pollutants-in-the-environment-current-and-further-implications",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/4606.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5101",title:"Invertebrates",subtitle:"Experimental Models in Toxicity Screening",isOpenForSubmission:!1,hash:"ebef5298af7d87ad3c9c7f5fe808fa2c",slug:"invertebrates-experimental-models-in-toxicity-screening",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/5101.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5358",title:"Soil Contamination",subtitle:"Current Consequences and Further Solutions",isOpenForSubmission:!1,hash:"e4d136df9f1658ae17f3ba7b3c992460",slug:"soil-contamination-current-consequences-and-further-solutions",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/5358.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4616",title:"Nanomaterials",subtitle:"Toxicity and Risk Assessment",isOpenForSubmission:!1,hash:"a96b5d34ca84aecacbab309ba1e7e563",slug:"nanomaterials-toxicity-and-risk-assessment",bookSignature:"Sonia Soloneski and Marcelo L. Larramendy",coverURL:"https://cdn.intechopen.com/books/images_new/4616.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6310",title:"Genotoxicity",subtitle:"A Predictable Risk to Our Actual World",isOpenForSubmission:!1,hash:"14a0966cec5283fdbc781a6bb47ed4e3",slug:"genotoxicity-a-predictable-risk-to-our-actual-world",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/6310.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"65200",slug:"corrigendum-to-evaluation-of-psoriasis-patients",title:"Corrigendum to: Evaluation of Psoriasis Patients",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/65200.pdf",downloadPdfUrl:"/chapter/pdf-download/65200",previewPdfUrl:"/chapter/pdf-preview/65200",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/65200",risUrl:"/chapter/ris/65200",chapter:{id:"63332",slug:"evaluation-of-psoriasis-patients",signatures:"Meda Sandra Orasan, Iulia Ioana Roman and Andrei Coneac",dateSubmitted:"April 17th 2018",dateReviewed:"June 26th 2018",datePrePublished:"November 5th 2018",datePublished:"July 17th 2019",book:{id:"7045",title:"Tailored Treatments in Psoriatic Patients",subtitle:null,fullTitle:"Tailored Treatments in Psoriatic Patients",slug:"tailored-treatments-in-psoriatic-patients",publishedDate:"July 17th 2019",bookSignature:"Shahin Aghaei",coverURL:"https://cdn.intechopen.com/books/images_new/7045.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"64024",title:"Dr.",name:"Shahin",middleName:null,surname:"Aghaei",slug:"shahin-aghaei",fullName:"Shahin Aghaei"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"202125",title:"Dr.",name:"Meda",middleName:"Sandra",surname:"Orasan",fullName:"Meda Orasan",slug:"meda-orasan",email:"meda2002m@yahoo.com",position:null,institution:{name:"Iuliu Hațieganu University of Medicine and Pharmacy",institutionURL:null,country:{name:"Romania"}}},{id:"205669",title:"Dr.",name:"Andrei",middleName:null,surname:"Coneac",fullName:"Andrei Coneac",slug:"andrei-coneac",email:"andrei.coneac@gmail.com",position:null,institution:null},{id:"255002",title:"Dr.",name:"Iulia Ioana",middleName:null,surname:"Roman",fullName:"Iulia Ioana Roman",slug:"iulia-ioana-roman",email:"iuliaroman09@gmail.com",position:null,institution:null}]}},chapter:{id:"63332",slug:"evaluation-of-psoriasis-patients",signatures:"Meda Sandra Orasan, Iulia Ioana Roman and Andrei Coneac",dateSubmitted:"April 17th 2018",dateReviewed:"June 26th 2018",datePrePublished:"November 5th 2018",datePublished:"July 17th 2019",book:{id:"7045",title:"Tailored Treatments in Psoriatic Patients",subtitle:null,fullTitle:"Tailored Treatments in Psoriatic Patients",slug:"tailored-treatments-in-psoriatic-patients",publishedDate:"July 17th 2019",bookSignature:"Shahin Aghaei",coverURL:"https://cdn.intechopen.com/books/images_new/7045.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"64024",title:"Dr.",name:"Shahin",middleName:null,surname:"Aghaei",slug:"shahin-aghaei",fullName:"Shahin Aghaei"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"202125",title:"Dr.",name:"Meda",middleName:"Sandra",surname:"Orasan",fullName:"Meda Orasan",slug:"meda-orasan",email:"meda2002m@yahoo.com",position:null,institution:{name:"Iuliu Hațieganu University of Medicine and Pharmacy",institutionURL:null,country:{name:"Romania"}}},{id:"205669",title:"Dr.",name:"Andrei",middleName:null,surname:"Coneac",fullName:"Andrei Coneac",slug:"andrei-coneac",email:"andrei.coneac@gmail.com",position:null,institution:null},{id:"255002",title:"Dr.",name:"Iulia Ioana",middleName:null,surname:"Roman",fullName:"Iulia Ioana Roman",slug:"iulia-ioana-roman",email:"iuliaroman09@gmail.com",position:null,institution:null}]},book:{id:"7045",title:"Tailored Treatments in Psoriatic Patients",subtitle:null,fullTitle:"Tailored Treatments in Psoriatic Patients",slug:"tailored-treatments-in-psoriatic-patients",publishedDate:"July 17th 2019",bookSignature:"Shahin Aghaei",coverURL:"https://cdn.intechopen.com/books/images_new/7045.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"64024",title:"Dr.",name:"Shahin",middleName:null,surname:"Aghaei",slug:"shahin-aghaei",fullName:"Shahin Aghaei"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"9992",leadTitle:null,title:"Updates in Volcanology – Transdisciplinary Nature of Volcano Science",subtitle:null,reviewType:"peer-reviewed",abstract:"
\r\n\tThis new book with a working title of "Volcanology - Updates in Volcanology" is a new edition of a successful IntechOpen book series initiated in 2012. The book intends to provide a snapshot of current hot topics in volcanology that receive elevated interest in the global research arena.
\r\n\r\n\tThis book calls contributions centered primarily (but not exclusively) in 6 topic areas currently enjoying strong research activity. The topics are:
\r\n\r\n\t1) new advances in understanding monogenetic volcanism,
\r\n\r\n\t2) the evolution of stratovolcanoes from their growth phase to their erosion,
\r\n\r\n\t3) understanding the link between small-volume silicic lava dome forming eruptions and extensive ignimbrite-producing mega-caldera flare-ups,
\r\n\r\n\t4) new development to define the role of water in volcanic eruptions,
\r\n\r\n\t5) new methods and techniques in volcano geology applications like geological mapping and
\r\n\r\n\t6) new researches on better documenting and quantifying geoheritage values of volcanic terrains and their utilization on volcanic hazard and disaster resilience applications.
\r\n\r\n\t
\r\n\tThe book equally expects submissions based on stand-alone research cases and review style summaries or more personal overviews of the outlined topics.
The neurofibromatoses are a heterogenous group of familial tumor predisposition syndromes that result from pathogenic variants in tumor suppressor genes leading to dysregulation in various cellular pathways. This dysregulation eventually leads to tumors of the central and peripheral nervous systems as well as multiorgan involvement. The incidence of Neurofibromatosis type 1 (NF1) is approximately 1 in every 2500–3500 births [1], while the incidence of neurofibromatosis type 2 (NF2) is approximately 1 in every 25,000–33,000 births [2]. Schwannomatosis (SWN) has been identified as a distinct entity with different genetic etiology and clinical phenotype from NF2, but it is difficult to assess the precise incidence of this condition. Although the tumors that develop most frequently in NF1, NF2 and SWN are histologically benign, they can cause significant neurologic disabilities and even mortality due to the involvement of the central and peripheral nervous systems. These tumors represent a unique therapeutic challenge due to the heterogeneity in severity and rate of progression among patients and hence novel therapeutic approaches are needed. In this chapter, we will review the recent studies in the field of neurofibromatosis therapeutics along with the collaborative efforts for innovative clinical trial designs.
\nThe establishment of the NFCTC in 2006 by the Department of Defense was a landmark in the field of NF therapeutics development [3]. The consortium has been in continuous operation since inception. It provides infrastructure, and shared resources across multiple institutions to generate resource-efficient clinical trials. The REiNS working groups are another clear example of the influence of collaboration among NF experts to advance the NF drug development efforts. The Children’s Tumor Foundation (CTF) has provided support to the NF community, including efforts to advance research as well as public education and patient support. In 2007, the CTF invested $4 million to launch the Neurofibromatosis Preclinical Consortium (NFPC) to test candidate drug therapies in NF1 and NF2 models. The Neurofibromatosis Therapeutic Acceleration (NTAP) was established as a private philanthropy to accelerate the development of effective therapeutics for pNFs and cNFs. NTAP has partnered with CTF in the evaluation of potential therapeutic agents in animal models of pNFs.
\nThe collaborative efforts among academic, federal regulatory, and private foundations have resulted in early successes in the NF therapeutic development. In February 2018, selumetinib, a MEK1/2 inhibitor co-developed by AstraZenca and Merck&Co, received breakthrough status from the FDA. Selumetinib was granted Orphan Drug Designation based on data from the phase II trial that tested selumetinib in pediatric patients with inoperable pNFs (NCT01362803) [4] and hence, selumetinib may become the first approved drug for NF. This success highlights the power of collaboration, which moved Selumetinib from a repurposed oncology drug to its current clinical success in NF patients. The funders involved for in this “MEK story” are the CTF, the National Institute of Health (NIH), the Congressionally Directed Medical Research Program (CDMRP) through NFCTC, and the NTAP at Johns Hopkins University [5].
\nUnderstanding of the pathogenesis and molecular landscape of the NF1-associated tumors has advanced dramatically in recent years. This advancement, along with the continued collaborative approaches across the research community, has fueled therapeutic development efforts against many of the NF1 manifestations. Therapeutic development in NF1 has been tumor-specific, due to the substantial heterogeneity of the development and behavior of NF1-associated tumors across and within patients. Plexiform neurofibromas (pNFs), the source of major morbidity in NF1, has been an area of major focus for therapeutic development, followed by other NF1-associated tumors including cutaneous neurofibromas (cNF), optic pathway gliomas (OPG), and malignant peripheral nerve sheath tumors (MPNST).
\nPlexiform neurofibromas (pNFs) affect up to 50% of NF1 patients and can involve any peripheral nerve [6, 7]. They occur most commonly in the trunk, followed by the extremities [6]. pNFs tend to grow most rapidly in early childhood and may increase by ≥20% per volume per year in young children [8]. Though surgery remains the mainstay for treatment of pNF, complete resection is virtually impossible due to the frequent involvement of adjacent normal tissue, and occasionally critical structures. Moreover, surgical resection is frequently challenging since pNF can cross tissue planes and involve multiple body regions. The most common morbidities leading to surgery are neurologic, disfigurement, and airway involvement [9]. A substantial risk of pNF regrowth after surgical resection has motivated the ongoing research to find non-invasive therapies for pNF.
\nThere are multiple ongoing clinical trials (Table 1) targeting pNF which represent a rapid expansion in the pNF therapeutic landscape. Though some of the tested drugs have failed to achieve the primary endpoint, they helped establish the natural history of the growth rates of pNF [10, 11]. The therapeutic development efforts in pNFs had shifted from testing “empirically,” usually cytotoxic, agents to agents being supported by well-established transitional studies. The first agent that showed radiographic response was imatinib, with a response rate of 17% [12]. Ras-pathway targeted therapy has been of particular interest, as it provides an opportunity for treating multiple manifestations of NF1 with one drug. For example, Selumetinib, which is a MEK (mitogen-activated protein kinase) inhibitor, has shown activity in pNF and low-grade gliomas (including OPG) associated with NF1 [13].
\nDrug | \nTarget | \nPhase | \nAge (y) | \nEndpoints | \nResults | \n
---|---|---|---|---|---|
Thalidomide [14] | \nAngiogenesis | \nI | \n>5 | \nORR | \nCompleted/unclear benefit | \n
Sirolimus [15] NCT00634270 | \nmTOR | \nII | \n>3 | \n3D ORR, TTP | \nModest increase in TTP, no objective response | \n
Sorafenib [16] NCT00727233 | \nRaf kinase, c-kit, PDGF, VEGFR2,3 | \nI | \n3–18 | \n3D ORR | \nIntolerable, decrease in QOL due to pain, no objective response | \n
Pirfenidone [17, 18] NCT00076102 | \nFibroblast proliferation | \nI, II | \n3–21 | \n3D ORR | \nCompleted, no objective response | \n
Cediranib NCT00326872 | \nVEGFR-1, -2, -3 | \nII | \n≥18 | \n3D ORR | \nTerminated due to slow accrual | \n
Tipifarnib [19] NCT00021541 | \nFarnesyl transferase | \nI, II | \n3–25 | \nTTP, 3D ORR | \nCompleted, No difference in TTP | \n
PEG-Interferon alpha 2b [20, 21] NCT00396019 | \nImmune, angiogenesis | \nI, II | \n18 months–21 years in phase II | \nTTP, 3D ORR | \nDoubled TTP, 3D ORR less than 20% | \n
Vinblastine/Methotrexate NCT00030264 | \nCytotoxic | \nII | \n≤25 | \nTTP | \nCompleted, pending results | \n
Celecoxib; PEG-Interferon alpha 2b NCT00846430 | \nImmune, angiogenesis | \nII | \n2–30 | \nSymptoms improvement, ORR | \nActive, not recruiting | \n
Nilotinib NCT01275586 | \nBCR-ABL, PDGFR, c-kit | \nPilot | \n≥18 | \nRECIST,3D ORR | \nCompleted | \n
Everolimus [22] NCT01412892 | \nmTOR | \nII | \n18–60 | \n3D ORR | \nCompleted, no objective response | \n
Everolimus NCT01365468 | \nmTOR | \nII | \n>10 | \n3D ORR, TTP | \nTerminated due to slow accrual | \n
Imatinib [23] NCT01673009 | \nc-kit, PDGFR | \nII | \n3–65 | \nRECIST, 3D ORR | \n17% 3D ORR | \n
Sunitinib NCT01402817 | \nPDGFR, VEGFR, c-kit | \nII | \n3–65 | \n3D ORR | \nTerminated (1 patient died) | \n
Pexidartinib [24] NCT02390752 | \nc-kit, FLT3, CSF1R | \nI, II | \n3–31 | \nORR | \nRecruiting | \n
Cabozantinib NCT02101736 | \nRET, c-MET, VEGFR | \nII | \n≥3 | \n3D ORR | \nRecruiting | \n
Trametinib NCT02124772 | \nMEK | \nI | \n1 month–17 years | \nPK, PD, toxicity | \nRecruiting | \n
PD-0325901 [25] NCT02096471 | \nMEK | \nII | \n≥16 | \n3D ORR | \nCompleted, 42% 3D ORR | \n
Selumetinib [26] NCT01362803 | \nMEK | \nI, II | \n2–18 | \n3D ORR | \nActive, not recruiting, 71% 3D ORR | \n
Selumetinib NCT02407405 | \nMEK | \nII | \n≥18 | \n3D ORR | \nRecruiting | \n
Binimetinib NCT03231306 | \nMEK | \nII | \n≥1 | \n3D ORR | \nRecruiting | \n
Selumetinib (intermittent dosing) NCT03326388 | \nMEK | \nI, II | \n3–18 | \nToxicity, 3D ORR | \nActive, not recruiting | \n
Trametinib NCT03363217 | \nMEK | \nII | \n1 month–25 years | \n3D ORR, TTP RECIST | \nRecruiting | \n
Imatinib (in pNF with airway involvement) NCT03688568 | \nc-kit, PDGFR | \nII | \n6 months–12 years | \nSleep study/PFT, 3D ORR | \nRecruiting | \n
Clinical trials for neurofibromatosis type 1-associated plexiform neurofibromas.
\n
Optic pathway glioma (OPG) is the most common form of glioma seen in individuals with NF1. While 15–20% of children with NF1 will develop OPG [27, 28] only 30–50% will be symptomatic and one-third will require therapeutic intervention [29]. In those with confirmed decline in visual acuity (VA) or involvement in the hypothalamus, chemotherapy is the mainstay of treatment. First-line chemotherapeutic agents include vincristine and carboplatin [30], while second-line agents include vinblastine [31], vinorelbine [32], and temozolomide [33]. There is a report of four cases of refractory OPG (two sporadic and two NF1-associated OPG) that showed marked improvement in VA following treatment with bevacizumab [34]. These agents rarely restore the premorbid visual acuity and the aim of treatment is usually to stabilize disease and prevent further worsening [35, 36]. Radiotherapy is usually avoided in NF1-associated OPG for concern of secondary tumors [37] and moya moya syndrome [38] Surgical excision of OPG is not feasible due to the tumor location and is usually reserved for instances of complete loss of vision, severe proptosis, or hydrocephalus.
\nRecently, small molecule inhibitors have been used for refractory OPG in clinical trials (Table 2). Among these agents, selumetinib has shown promising results in phase II studies and was proven to be active in recurrent, refractory or progressive NF1-associated pediatric low-grade glioma [39].
\nDrug | \nTarget | \nPhase | \nAge | \nEndpoints | \nStatus | \n
---|---|---|---|---|---|
Vinblastine +/− Bevacizumab NCT02840409 | \nCytotoxic/VEGF | \nII | \n6 months–18 years | \nResponse rate, OS, PFS, visual outcome measures, OCT | \nRecruiting | \n
Pegylated interferon NCT02343224 | \nTumor microenvironment | \nII | \n3–18 years | \nResponse rate | \nRecruiting | \n
Pomalidomide NCT02415153 | \nAngiogenesis/immunomodulation | \nI | \n3–20 years | \nToxicity, MTD | \nActive, not recruiting | \n
Lenalidomide NCT01553149 | \nAngiogenesis/immunomodulation | \nII | \n0–21 years | \nResponse rate | \nActive, not recruiting | \n
Everolimus (RAD0001) NCT01158651 | \nmTOR | \nII | \n1–21 years | \nResponse rate | \nActive, not recruiting | \n
Binimetinib (MEK162) NCT02285439 | \nMEK | \nI/II | \n1–18 years | \nMTD, response rate | \nRecruiting | \n
Binimetinib (MEK162) NCT01885195 | \nMEK | \nII | \nOlder than 18 years | \nResponse rate | \nCompleted (pending results) | \n
Selumetinib NCT01089101 | \nMEK | \nI/II | \n3–21 years | \nSafety, MTD, Response rate | \nRecruiting | \n
Clinical trials for optic pathway gliomas (OPG) and other gliomas associated with neurofibromatosis type 1.
\n
Unnecessary cytotoxic therapies for OPG should be avoided, as many OPGs remain asymptomatic and some even regress over time [28]. One of the efforts to standardize the VA assessment in clinical trials for NF1-associated OPG is through using optic coherence tomography (OCT) [40, 41]. OCT provides an objective assessment of the retinal nerve fiber layer thickness. OCT is a noninvasive tool to monitor children with OPG in whom, especially the youngest ones, traditional methods of VA assessment is challenging [42]. Another objective noninvasive tool to asses VA in NF1-associated OPG is automated tractography of the optic radiation that was validated in a recent study [43].
\nA retrospective study that analyzed the clinical and pathological features of gliomas in 100 individuals with NF1 emphasized the wide histologic spectrum of gliomas in those with NF1 [44]. Indeed, individuals with NF1 have an increased risk of malignant gliomas compared with the general population [45], but there are confounding reports on glioblastoma prognosis in those with NF1 vs. cases without NF1 [46, 47]. A recent study analyzed the molecular landscape of gliomas in NF1 and showed that 50% of low-grade gliomas displayed an immune signature, T-lymphocytic infiltrate, and increased neoantigen load [48], findings that may influence future clinical trials in NF1-associated gliomas.
\nMalignant peripheral nerve sheath tumors (MPNSTs) are rare high-grade sarcomas with poor prognosis [49]. MPNSTs occur more frequently in those with NF1 compared with the general population, with a lifetime risk of 8–13% [50]. Several studies have not shown a significant difference in the molecular landscape between sporadic and NF1-associated MPNSTs [51, 52]. FDG-PET remains the gold standard noninvasive diagnostic tool for MPNSTs, with 89–100% sensitivity and 72–95 specificity [53, 54]. Surgical resection with negative margins is the mainstay of treatment [55], though that is not usually feasible. Use of adjuvant radiotherapy to induce local control in MPSNTs failed to show improvement in overall survival in NF1-associated MPNSTs [56].
\nThere are limited chemotherapeutic options, including agents like doxorubicin, and ifosfamide [57, 58]. A phase II study of bevacizumab and everolimus that enrolled 25 individuals (17 had NF1-associated MPNST) did not show a clinical benefit (defined as complete response, partial response or stable disease for ≥4 months) [59]. Although preclinical studies showed EGFR amplification in MPSNT [60], EGFR inhibitors did not show clinical activity against MPNST in clinical trials. A few studies have been conducted in sarcomas using targeted therapy, and these have not shown clinical activity; tested drugs included imatinib [61], dasatinib [62], sorafenib [63], and erlotinib [64]. These negative studies emphasize the importance of developing xenografts to explore new therapeutic targets and explore pathways of interest like the NF1/P53-mutant transgenic MPNST model [65, 66, 67].
\nCombined targeted therapy has been used to exploit cellular vulnerabilities of cancer cells, as in RAS-driven tumors which are refractory to conventional therapies. A preclinical study has shown dramatic tumor shrinkage in a transgenic MPNST mouse model in response to combined HSP90 and mTOR inhibition [68]. This promising preclinical work had led to a phase I/II study of gantespib, a novel injectable inhibitor of HSP90 and the mTOR inhibitor, sirolimus. The study enrolled 20 participants (NCT02008877) and results are pending [69]. Another novel approach undergoing phase I study utilizes the oncolytic potential of the genetically engineered injectable measles virus Edmonston vaccine strain (MVEdm) that encodes thyroid sodium iodide symporter [70] (Table 3).
\nDrug | \nTarget | \nPhase | \nAge (years) | \nEndpoints | \nStatus | \n
---|---|---|---|---|---|
EGFR806 CAR-T cell NCT03618381 | \nImmunotherapy | \nI | \n1–26 | \nToxicity | \nRecruiting | \n
Selumetinib and Sirolimus NCT03433183 | \nMEK and mTOR | \nII | \n≥12 | \nCBR, PFS, OS | \nActive, not recruiting | \n
Injectable MVEdm vaccine strain NCT02700230 | \nOncolytic virotherapy | \nI | \n≥18 | \nToxicity, MTD, ORR | \nRecruiting | \n
Pazopanib vs. Sapanisertib NCT02601209 | \nPDGFR, VEGFR, c-kit (Pazopanib), TORC1&2 (Sapanisertib) | \nI (Sapanisertib), II | \n≥18 | \nMTD, PFS, ORR | \nActive, not recruiting | \n
Lorvotuzumab mertansine NCT02452554 | \nCD-56 antibody | \nII | \n1–30 | \nRECIST | \nActive, not recruiting | \n
Pexidartinib and Sirolimus NCT02584647 | \nc-kit, FLT3, CSF1R, mTOR | \nII | \n≥18 | \nPFS, OS | \nRecruiting | \n
Clinical trials for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
\n
Cutaneous neurofibromas (cNFs) are among the most common manifestations in NF1, affecting about 99% of patients with NF1 [71]. cNFs are unlikely to undergo malignant transformation or to cause fatal complications or severe neurologic disability. Nevertheless, cNFs are considered one of the greatest concerns in patients, especially adults, with NF1. These concerns are mainly due to disfigurement and dysesthesia, causing substantial psychological distress and negative body image perception [72]. There is immense variability in cNF among patients with NF1 with respect to size, location, age at first presentation, associated symptoms, and number. These factors affect the therapeutic approach to cNFs and emphasize the need for reproducible and reliable endpoints to ensure clinical success for tested agents.
\nClinical management for cNF involves surveillance or procedure-based therapy. Conventional surgical resection promotes complete removal of the lesion, but there are obstacles, including limited number of lesions that can be treated in a single session and the scarring that may be induced by surgical resection. Other alternatives include electrodessication, which remove cNFs through dehydration and denaturation [73]. This allows for removal of large numbers (up to thousands) of cNFs in one session, but it requires general anesthesia and may cause scarring and pigmentation changes. A retrospective study of 106 individuals with multiple, small cNFs treated with CO2 laser ablation reported >90% patient satisfaction, yet a local infection rate was reported to be 15% [74]. Other procedure-based therapies reported in cNFs are laser photocoagulation [75] and radiofrequency ablation [76]. Another approach using local drug/device combinations is the photodynamic therapy (PDT), which is being tested in different cancers [77]. PDT in cNFs studies use a photosensitizer, 5-amino-levulinic acid, plus illumination with red light. PDT was evaluated in phase I study (NCT01682811) and a phase II study (NCT02728388) is active in a single US institution.
\nOne of the early efforts for treatment of cNFs and their associated symptoms used ketotifen [78]. Ketotifen is a histamine 1 receptor blocker which facilitates mast cell stabilization and; its use in NF1 is based on the finding of abundant mast cells in neurofibromas. Improvement in pain and pruritis has been reported, but objective tumor shrinkage has not been documented. Three drugs have been tested in cNFs using local therapeutic approaches; the first was ranibizumab, a vascular endothelial growth factor monoclonal antibody, which was injected intralesionally (NCT00657202). The overall effect of the treatment was minimal and the variability in the tumor volume assessment (measured by a caliper) limited the interpretation of the data. The second agent was topical imiquimod, which showed minimal efficacy in tumor shrinkage compared to baseline volume (measured by a caliper) (NCT00865644). The third agent was topical rapamycin, an mTOR inhibitor, which was initially tested in Tuberous Sclerosis Complex (TSC)-associated angiofibromas (NCT01031901) [79]. The study enrolled 52 patients with TSC and NF1 and data are expected.
\nDue to the relatively benign histology of cNFs and the likely need for long term therapy, there are special considerations pertaining to cNF drug development [80]. The safety profile of tested drugs is a major concern to physicians, regulators, patients and their caregiver. Also, the route of administration and cost are important considerations, as individuals with cNF are more likely to require treatment (either medication or intervention) for an extended period of time. The variant phenotype among affected persons, demographic differences, and the goal of treatment are important factor determining the type and timing of treatment.
\nThe above-mentioned considerations, especially the safety profile, make oral systemic therapies preferable for individuals with a heavy tumor burden. Everolimus, an oral mTOR inhibitor, was evaluated in a phase II study of disfiguring cNF associated with NF1 (NCT02334902). The study enrolled 22 patients and used photographic measurement of selected lesion to assess surface volume. While 5/22 patients withdrew due to adverse events, a very modest effect was reported in <20% of the participants [81]. Due to the promising results of using targeted therapied against MEK, selumetinib is being studied in NF1-associated cNFs (NCT02839720). The study is a phase II, multi-institutional, open label study with the primary outcome measure being the change in the size of cNFs assessed by digital photography and caliper measurements.
\nThe Clinical Trial Design and Development REiNS subgroup, involving experts from different settings, has presented the priorities and challenges associated with conducting clinical trials targeting cNF in NF1 [82]. The subgroup members reviewed key topics like natural history, assessment methods, functional endpoints, safety, and development strategies. One of the most important topics, which pose a major challenge in cNF clinical trials, is the measurement of outcomes. Methods of measurement that have been used include calipers, digital and volume photography, ultrasound, and MRI. The subgroup members support considering clinically meaningful measures of effectiveness in interpreting changes in tumor size or number. Tumor size reduction that correlates with improved pain control or discomfort is more clinically meaningful than the crude number or size of the tumors. New approaches, such as high-frequency ultrasound or optical coherence tomography, may be able to address some of the limitations of the conventional methods like MRI, photography or caliper measurement. These new approaches need to be validated through additional studies. The subgroup members recommend several key factors when designing clinical trials on cNF, including timing to initiate intervention, eligibility criteria to ensure diversity, mechanism of the intervention, route of administration, safety monitoring, and regulatory considerations.
\nNF2 is an autosomal dominant disorder that affects the central and peripheral nervous systems. NF2 has an estimated incidence of 1 in 25,000–33,000 births, making it far less common than NF1 [83]. Vestibular schwannomas (VS) are considered the hallmark of NF2, and bilateral VS fulfill the clinical diagnosis of definite NF2 [84]. The average age at diagnosis in NF2-associated VS is about 27 years [85]; diagnosis in childhood predicts a severe phenotype and unfavorable prognosis [86]. Though VS are slowly progressive tumors, they can cause significant neurologic disability, including hearing loss and eventually deafness, balance problems, and brain stem compression [87]. The other common tumor associated with NF2 is meningioma, which is the most common intracranial tumor worldwide. Up to half of individuals with NF2 develop meningiomas [88], and despite benign histology, they may lead to a shortened life expectancy [89].
\nThe loss of the tumor suppressor protein merlin in NF2 leads to activation of prosurvival pathways via RAS modulation. Hence, NF2 shares many of the same targets identified in NF1. Merlin is absent not only in NF2-associated VS, but also in sporadic VS [90]. This observation is important as it may point to a shared therapeutic pathway between NF2-associated VS and sporadic VS [91].
\nThough surgery remains the mainstay of treatment in sporadic VS, or stereotactic radiosurgery (SRS) for tumors <3 cm [92], these approaches have proved to be less efficacious in NF2-associated VS, with high rate of complications, including facial nerve weakness, hearing loss, and headache [93, 94]. Moreover, there are growing concerns about utilizing radiation therapy in NF2 due to risk of late malignant transformation [95]. Some of the challenges that face NF2 clinical trials are the substantial variability in disease severity across individuals with NF2, the lack of clear association between the rate of VS growth and the rate of hearing loss, and the variable growth rates between the right and the left VS in same patient [96]. A prospective study that highlighted the lack of correlation between VS size or growth rate and rate of hearing loss was published in 2014 and included 120 individuals with NF2-associated VS (total of 200 VS) [97]. The investigators used word recognition score (WRS) as an objective measurement for hearing decline and defined radiographic tumor growth as ≥20% increase in tumor volume compared with baseline. The study showed that the mean rate of hearing decline from diagnosis was 5% at 1 year and 16% at 3 years, while the rate of VS tumor graphic progression was 31% at 1 year and 79% at 3 years. The median time to progression (14 months) was significantly shorter than the median time to hearing decline (62 months) [93]. This study, along with prior reports, elucidated the natural history of individuals with NF2 to help to determine the most appropriate timing for intervention [81, 83, 98].
\nClinical trials for NF2 have been focused on vestibular schwannomas, since loss of hearing is often the most pressing concern in individuals with NF2. A group of 36 international researchers, physicians, representatives from the pharmaceutical industry, and patient advocates held a workshop to provide consensus recommendations to accelerate clinical trials progress in NF2 [99]. The group provided recommendations on participant selection, clinically meaningful and feasible endpoints, the clinical trials models most appropriate for NF2, and candidate therapeutic agents for NF2.
\nDifferent cellular pathways have been targeted in clinical trials for NF2-associated tumors (Table 4), with mixed responses. One of the most promising agents used in NF2 is bevacizumab, which was initially given on a compassionate use basis for adults with NF2-associated VS with severe disability [100, 101]. In these reports, 6 of 10 participants had ≥20% reduction in tumor volume and significantly improved hearing. The promising results led to designing two phase II clinical trials using bevacizumab in persons with NF2 who suffered from progressive hearing loss. A preliminary report from one of these 2 trials that enrolled 22 participants showed that the overall hearing and radiographic response rates were 41 and 23% respectively, though pediatric participants appeared to benefit less compared to adults (NCT01767792) [102]. Bevacizumab was used in a dose of 10 mg/kg every 2 weeks for 6 months, followed by 5 mg/kg every 3 weeks for 18 months; this regimen was well tolerated.
\nDrug | \nTarget | \nPhase | \nAge (years) | \nEndpoints | \nStatus | \n
---|---|---|---|---|---|
Everolimus [104] NCT01419639 | \nmTOR | \nII | \n≥3 | \nVS: 15% volume reductions | \nNo RR | \n
Everolimus [105] NCT01490476 | \nmTOR | \nII | \n≥15 | \nVS: volume reduction | \nNo RR | \n
Everolimus NCT01345136 | \nmTOR | \nII | \n16–65 | \nVS: volume reduction | \nActive, not recruiting | \n
Everolimus NCT01880749 | \nmTOR | \nEarly phase I | \n≥18 | \nVS and MEN: tumor PK, molecular analysis | \nActive, not recruiting | \n
Lapatinib [106] NCT00973739 | \nEGFR/ErBb2 | \nII | \n4–80 | \nVS: 15% volume reduction | \n23.5% RR | \n
Lapatinib NCT00863122 | \nEGFR/ErBb2 | \nEarly phase I | \n≥18 | \nVS: tumor PK, molecular analysis | \nCompleted, pending results | \n
Axitinib NCT02129647 | \nVEGF, c-kit, PDGFR | \nII | \n≥18 | \nVS: 20% volume reduction | \nActive, not recruiting | \n
Nilotinib NCT01201538 | \nPDGF, c-kit | \nII | \n≥18 | \nVS: 20% volume reduction | \nTerminated | \n
PTC 299 NCT00911248 | \nVEGF | \nII | \n≥18 | \nVS: Tumor volume or WRS | \nTerminated | \n
Endostatin NCT02104323 | \nAnti-angiogenic | \nII | \n16–30 | \nTumor volume | \nCompleted, pending results | \n
AR-42 NCT02104323 | \nHDAC | \nEarly phase I | \n≥18 | \nVS and MEN: tumor PK, molecular analysis | \nActive, not recruiting | \n
Bevacizumab [107] NCT01207687 | \nVEGF | \nII | \n≥12 | \nVS: hearing response measured by WRS | \nCompleted, hearing response 36% | \n
Bevacizumab[102] \n NCT01767792 | \nVEGF | \nII | \n≥12 | \nVS: hearing response measured by WRS | \nActive, not recruiting, hearing response 41%, RR 23% | \n
Acetylsalicylic acid NCT03079999 | \nAntiplatelet, anti-inflammatory | \nII, randomized, placebo-control | \n≥12 | \nVS: PFS | \nActive | \n
Vistusertib (AZD2014) NCT02831257 | \nmTORC1, mTORC2 | \nII | \n≥18 | \nMEN: RR using volumetric MRI | \nActive, not recruiting | \n
Selumetinib NCT03095248 | \nMEK | \nII | \n3–45 | \nVS, MEN, and ependymoma: hearing response measured by WRS, RR | \nActive | \n
Clinical trials in Neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
\n
NF2 shares many of the same targets identified in NF1; hence, some of the therapeutic agents tested in NF1 are being tested in NF2, including everolimus (NCT01345136), sorafenib, and selumetinib (NCT03095248). The dual mTROC1 and mTORC2 inhibitor, vistusertib (AZD2014), is used in a phase II study for NF2 patients with progressive or symptomatic meningiomas (NCT02831257). While the primary outcome for this study is the radiographic response rate for meningioma using volumetric MRI scans, the secondary outcomes include response assessment for VS and non-target meningioma using volumetric MRI. The NFCTC has approved using crizotinib, a MET and ALK inhibitor, in a phase II study for children and adults with NF2-associated progressive VS. There are promising preclinical studies identifying crizotinib as a potent inhibitor of NF2-null Schwann cell proliferation in vitro and tumor growth in vivo [103]. The goal for these clinical trials is to assess the hearing response rate as a clinically meaningful endpoint and to assess tolerability and long term effects of the tested agents, as well as identify biomarkers that can predict outcomes.
\nSchwannomatosis (SWN), as the name implies, is characterized by the development of multiple peripheral nerve schwannomas, without concomitant involvement of the vestibular nerve, and, less commonly, meningiomas [108, 109, 110]. Since the schwannoma is the most common tumor in NF2 and SWN, there can be overlap between the two syndromes. SWN is a distinct entity with different clinical phenotype and genetic etiology from NF2. Germline mutations in SMARCB1 and LZTR1, both tumor suppressor genes, have been identified in SWN [111, 112, 113]. Unlike NF1 and NF2, pain is the most common symptom reported by individuals affected with SWN, with 68% reporting chronic pain in SWN in a retrospective study [114].
\nSurgical resection is considered the treatment of choice for symptomatic schwannomas for pain relief, though local recurrence is not uncommon. Patients usually require multiple surgical resections due to pain, focal neurologic deficits, or myelopathy [113]. Radiotherapy is reserved for those with life-threatening or enlarging tumors, and in rare occasions, malignant schwannomas. There are no available safety studies with respect to radiotherapy-induced malignant transformation in SWN, though theoretically it is possible given the available data from NF1, and NF2 studies.
\nUp to date, no clinical trials have been conducted in the setting of SWN and no known effective therapies exist. A case report was published using bevacizumab in one individual with SWN-associated refractory pain with a remarkable response in pain control [115].
\nMost early clinical trials for patients with neurofibromatoses used designs and endpoints similar to oncology trials. However, there are major differences in natural history, disease manifestations, and overall prognosis between patients with NF and those with cancers. Hence, there was an unmet need to establish standardized endpoints in NF clinical trials that will allow precise data interpretation and the ability to assess efficacy across different studies. The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration was established in 2011 at the Children’s Tumor Foundation (CTF) meeting to achieve consensus about the design for future clinical trials with major emphasis on endpoints. The collaboration included 7 working groups; disease biomarkers; whole-body MRI; functional, visual, patient-reported, and neurocognitive outcome; and imaging for tumor response. Later, two more working groups were added; cutaneous neurofibromas, and patient representation [116].
\nThe REiNS Collaboration published the initial recommendations for clinical trials endpoint in 2013 [117]. MRI with volumetric analysis was recommended as the standard imaging metric for pNF and VS in NF1 and NF2 clinical trials [118]. A 20% volume change was chosen to indicate an increase or decrease in the tumor size. MRI analysis requires central review to ensure consistent results. This is a time and resource intensive tool; thus, the development of methods that can be incorporated into routine clinical practice and can be performed more easily is warranted. Whole-body MRI imaging (WB-MRI) may serve as an endpoint in clinical trials that target multiple tumors. The working group concluded that while WB-MRI is feasible for identifying tumors using both 1.5 T and 3.0 T systems, choosing a standardized image acquisition and analysis methods is crucial for applying WB-MRIs as a tool for assessing tumors in NF [119]. For clinical trials targeting NF2-associated VS, the REiNS functional outcomes group endorsed the use of maximum word recognition score as the primary endpoint for hearing. The group recommended using the measurement of improvement in lip excursion (SMILE) system for studies of facial function [120]. For clinical trials targeting NF-associated OPG, the visual outcomes working group recommended the use of visual acuity as the primary endpoint, as opposed to measurement of tumor size [121]. The group also recommended assessing the optic disc for pallor to allow accurate interpretation of the visual acuity. Regarding the neurocognitive outcomes, the working group concluded that The Digit Span (DS) subtest from the Wechsler scales is the most appropriate performance-based outcome measure, as it provides the best psychometrics, feasibility, and utility across a wide age range, and is extensively used in previous research [122]. For similar reasons, the Conners scale achieved the highest ratings of behavioral questionnaires and is considered the most appropriate observe-rated outcome measure.
\nIt is uncommon for pNF to cause airway compromise or pulmonary dysfunction, yet airway pNFs are clinically important. The REiNS functional outcomes group developed consensus recommendations for sleep and pulmonary outcome endpoints in airway pNFs [123]. The group endorsed using the apnea hypopnea index (AHI) as the primary sleep endpoint, and pulmonary resistance at 10 Hz (R10) of forced expiratory volume in 1 or 0.75 seconds (FEV1 or FEV 0.75) as the primary pulmonary endpoint. The group also identified secondary sleep and pulmonary outcomes. Measures of sleep and pulmonary function may be more clinically meaningful as endpoints than changes in tumor size in clinical trials targeting airway pNFs. Regarding patient-reported outcomes (PRO) of pain and physical function in NF clinical trials, the REiNS working group recommended the numeric rating scale-11 (NRS-11) to assess pain intensity for age 8 years and older [124]. To assess pain interference, the group recommended the Pain Interference Index in pediatric studies and the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Interference Scale in adult studies. PROMIS Physical Function Scale was deemed the most appropriate for NF trials to assess the physical functioning domain. The REiNS disease biomarkers working group reported consensus recommendations to provide clinicians and researches with a common set of guidelines to collect and store biospecimens and for establishment of biobanks for neurofibromatoses [125]. The group described the existing biomarkers in NF and report consensus recommendations for standard operation procedures to standardize sample collection and methodology protocols to promote comparison between studies.
\nDrug discovery is a very costly and lengthy process, which may take up to 10 years from first-in-human dosing to approval [126]. This process is usually preceded by years of extensive preclinical research to identify suitable targets for clinical development. The REiNS International Collaboration continues to work on developing consensus endpoints in NF clinical trials and to promote early engagement with FDA and other industry partners to accelerate the drug development and approval for NF-associated tumors.
\nThe field of NF therapeutics is at inflection point. Several clinical trials have been conducted targeting various manifestations of NF and more studies are ongoing. The alignment of endpoints along with utilizing validated clinical outcomes measures represents a priority for therapeutic development for NF. Fortunately, there is a growing interest in NF, which is drawing the attention of pharmaceutical and biotechnology companies to grow the pipeline for NF targeted therapy. These efforts are combined with several ongoing laboratory and preclinical studies that provide unique opportunities to study the complex biology and natural history of NF-associated tumor. The US breakthrough therapy designation that was granted to Selumetinib in NF1 endorses the critical need for partnership among the major consortia and funders to accelerate the therapeutics development efforts in the NF field.
\nMina Lobbous and Bruce Korf report no disclosures relative to the manuscript.
\n"Open access contributes to scientific excellence and integrity. It opens up research results to wider analysis. It allows research results to be reused for new discoveries. And it enables the multi-disciplinary research that is needed to solve global 21st century problems. Open access connects science with society. It allows the public to engage with research. To go behind the headlines. And look at the scientific evidence. And it enables policy makers to draw on innovative solutions to societal challenges".
\n\nCarlos Moedas, the European Commissioner for Research Science and Innovation at the STM Annual Frankfurt Conference, October 2016.
",metaTitle:"About Open Access",metaDescription:"Open access contributes to scientific excellence and integrity. It opens up research results to wider analysis. It allows research results to be reused for new discoveries. And it enables the multi-disciplinary research that is needed to solve global 21st century problems. Open access connects science with society. It allows the public to engage with research. To go behind the headlines. And look at the scientific evidence. And it enables policy makers to draw on innovative solutions to societal challenges.\n\nCarlos Moedas, the European Commissioner for Research Science and Innovation at the STM Annual Frankfurt Conference, October 2016.",metaKeywords:null,canonicalURL:"about-open-access",contentRaw:'[{"type":"htmlEditorComponent","content":"The Open Access publishing movement started in the early 2000s when academic leaders from around the world participated in the formation of the Budapest Initiative. They developed recommendations for an Open Access publishing process, “which has worked for the past decade to provide the public with unrestricted, free access to scholarly research—much of which is publicly funded. Making the research publicly available to everyone—free of charge and without most copyright and licensing restrictions—will accelerate scientific research efforts and allow authors to reach a larger number of readers” (reference: http://www.budapestopenaccessinitiative.org)
\\n\\nIntechOpen’s co-founders, both scientists themselves, created the company while undertaking research in robotics at Vienna University. Their goal was to spread research freely “for scientists, by scientists’ to the rest of the world via the Open Access publishing model. The company soon became a signatory of the Budapest Initiative, which currently has more than 1000 supporting organizations worldwide, ranging from universities to funders.
\\n\\nAt IntechOpen today, we are still as committed to working with organizations and people who care about scientific discovery, to putting the academic needs of the scientific community first, and to providing an Open Access environment where scientists can maximize their contribution to scientific advancement. By opening up access to the world’s scientific research articles and book chapters, we aim to facilitate greater opportunity for collaboration, scientific discovery and progress. We subscribe wholeheartedly to the Open Access definition:
\\n\\n“By “open access” to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited” (reference: http://www.budapestopenaccessinitiative.org)
\\n\\nOAI-PMH
\\n\\nAs a firm believer in the wider dissemination of knowledge, IntechOpen supports the Open Access Initiative Protocol for Metadata Harvesting (OAI-PMH Version 2.0). Read more
\\n\\nLicense
\\n\\nBook chapters published in edited volumes are distributed under the Creative Commons Attribution 3.0 Unported License (CC BY 3.0). IntechOpen upholds a very flexible Copyright Policy. There is no copyright transfer to the publisher and Authors retain exclusive copyright to their work. All Monographs/Compacts are distributed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Read more
\\n\\nPeer Review Policies
\\n\\nAll scientific works are Peer Reviewed prior to publishing. Read more
\\n\\nOA Publishing Fees
\\n\\nThe Open Access publishing model employed by IntechOpen eliminates subscription charges and pay-per-view fees, enabling readers to access research at no cost. In order to sustain operations and keep our publications freely accessible we levy an Open Access Publishing Fee for manuscripts, which helps us cover the costs of editorial work and the production of books. Read more
\\n\\nDigital Archiving Policy
\\n\\nIntechOpen is committed to ensuring the long-term preservation and the availability of all scholarly research we publish. We employ a variety of means to enable us to deliver on our commitments to the scientific community. Apart from preservation by the Croatian National Library (for publications prior to April 18, 2018) and the British Library (for publications after April 18, 2018), our entire catalogue is preserved in the CLOCKSS archive.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'The Open Access publishing movement started in the early 2000s when academic leaders from around the world participated in the formation of the Budapest Initiative. They developed recommendations for an Open Access publishing process, “which has worked for the past decade to provide the public with unrestricted, free access to scholarly research—much of which is publicly funded. Making the research publicly available to everyone—free of charge and without most copyright and licensing restrictions—will accelerate scientific research efforts and allow authors to reach a larger number of readers” (reference: http://www.budapestopenaccessinitiative.org)
\n\nIntechOpen’s co-founders, both scientists themselves, created the company while undertaking research in robotics at Vienna University. Their goal was to spread research freely “for scientists, by scientists’ to the rest of the world via the Open Access publishing model. The company soon became a signatory of the Budapest Initiative, which currently has more than 1000 supporting organizations worldwide, ranging from universities to funders.
\n\nAt IntechOpen today, we are still as committed to working with organizations and people who care about scientific discovery, to putting the academic needs of the scientific community first, and to providing an Open Access environment where scientists can maximize their contribution to scientific advancement. By opening up access to the world’s scientific research articles and book chapters, we aim to facilitate greater opportunity for collaboration, scientific discovery and progress. We subscribe wholeheartedly to the Open Access definition:
\n\n“By “open access” to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited” (reference: http://www.budapestopenaccessinitiative.org)
\n\nOAI-PMH
\n\nAs a firm believer in the wider dissemination of knowledge, IntechOpen supports the Open Access Initiative Protocol for Metadata Harvesting (OAI-PMH Version 2.0). Read more
\n\nLicense
\n\nBook chapters published in edited volumes are distributed under the Creative Commons Attribution 3.0 Unported License (CC BY 3.0). IntechOpen upholds a very flexible Copyright Policy. There is no copyright transfer to the publisher and Authors retain exclusive copyright to their work. All Monographs/Compacts are distributed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Read more
\n\nPeer Review Policies
\n\nAll scientific works are Peer Reviewed prior to publishing. Read more
\n\nOA Publishing Fees
\n\nThe Open Access publishing model employed by IntechOpen eliminates subscription charges and pay-per-view fees, enabling readers to access research at no cost. In order to sustain operations and keep our publications freely accessible we levy an Open Access Publishing Fee for manuscripts, which helps us cover the costs of editorial work and the production of books. Read more
\n\nDigital Archiving Policy
\n\nIntechOpen is committed to ensuring the long-term preservation and the availability of all scholarly research we publish. We employ a variety of means to enable us to deliver on our commitments to the scientific community. Apart from preservation by the Croatian National Library (for publications prior to April 18, 2018) and the British Library (for publications after April 18, 2018), our entire catalogue is preserved in the CLOCKSS archive.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5828},{group:"region",caption:"Middle and South America",value:2,count:5288},{group:"region",caption:"Africa",value:3,count:1765},{group:"region",caption:"Asia",value:4,count:10557},{group:"region",caption:"Australia and Oceania",value:5,count:909},{group:"region",caption:"Europe",value:6,count:15951}],offset:12,limit:12,total:119466},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"20"},books:[{type:"book",id:"10672",title:"Nonlinear Optics",subtitle:null,isOpenForSubmission:!0,hash:"cfe87b713a8bee22c19361b86b03d506",slug:null,bookSignature:"Dr. Boris I. Lembrikov",coverURL:"https://cdn.intechopen.com/books/images_new/10672.jpg",editedByType:null,editors:[{id:"2359",title:"Dr.",name:"Boris",surname:"Lembrikov",slug:"boris-lembrikov",fullName:"Boris Lembrikov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10674",title:"Topics on Quantum Information Science",subtitle:null,isOpenForSubmission:!0,hash:"d7481712cff0157cd8f849cba865727d",slug:null,bookSignature:"Prof. Sergio Curilef and Dr. Angel Ricardo Plastino",coverURL:"https://cdn.intechopen.com/books/images_new/10674.jpg",editedByType:null,editors:[{id:"125424",title:"Prof.",name:"Sergio",surname:"Curilef",slug:"sergio-curilef",fullName:"Sergio Curilef"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10852",title:"Electromagnetic Compatibility",subtitle:null,isOpenForSubmission:!0,hash:"f5d2cce3a2adbd5d108d3301ee97025b",slug:null,bookSignature:"Dr. Ahmed Kishk",coverURL:"https://cdn.intechopen.com/books/images_new/10852.jpg",editedByType:null,editors:[{id:"150146",title:"Dr.",name:"Ahmed",surname:"Kishk",slug:"ahmed-kishk",fullName:"Ahmed Kishk"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10921",title:"Plasma Science and Technology",subtitle:null,isOpenForSubmission:!0,hash:"c45670ef4b081fd9eebaf911b2b4627b",slug:null,bookSignature:"Dr. Aamir Shahzad",coverURL:"https://cdn.intechopen.com/books/images_new/10921.jpg",editedByType:null,editors:[{id:"288354",title:"Dr.",name:"Aamir",surname:"Shahzad",slug:"aamir-shahzad",fullName:"Aamir Shahzad"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10956",title:"Pulsed Lasers",subtitle:null,isOpenForSubmission:!0,hash:"88bd906b149fc3d1c5d6fdbd9916826c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10956.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:29},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:8},{group:"topic",caption:"Business, Management and Economics",value:7,count:4},{group:"topic",caption:"Chemistry",value:8,count:10},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:10},{group:"topic",caption:"Engineering",value:11,count:29},{group:"topic",caption:"Environmental Sciences",value:12,count:3},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:7},{group:"topic",caption:"Mathematics",value:15,count:3},{group:"topic",caption:"Medicine",value:16,count:53},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:4},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:4},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:5},popularBooks:{featuredBooks:[{type:"book",id:"9893",title:"Automation and Control",subtitle:null,isOpenForSubmission:!1,hash:"09ba24f6ac88af7f0aaff3029714ae48",slug:"automation-and-control",bookSignature:"Constantin Voloşencu, Serdar Küçük, José Guerrero and Oscar Valero",coverURL:"https://cdn.intechopen.com/books/images_new/9893.jpg",editors:[{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7016",title:"Cardiovascular Risk Factors in Pathology",subtitle:null,isOpenForSubmission:!1,hash:"7937d2c640c7515de372282c72ee5635",slug:"cardiovascular-risk-factors-in-pathology",bookSignature:"Alaeddin Abukabda, Maria Suciu and Minodora Andor",coverURL:"https://cdn.intechopen.com/books/images_new/7016.jpg",editors:[{id:"307873",title:"Ph.D.",name:"Alaeddin",middleName:null,surname:"Abukabda",slug:"alaeddin-abukabda",fullName:"Alaeddin Abukabda"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9873",title:"Strategies of Sustainable Solid Waste Management",subtitle:null,isOpenForSubmission:!1,hash:"59b5ceeeedaf7449a30629923569388c",slug:"strategies-of-sustainable-solid-waste-management",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/9873.jpg",editors:[{id:"144691",title:"Prof.",name:"Hosam M.",middleName:"M.",surname:"Saleh",slug:"hosam-m.-saleh",fullName:"Hosam M. Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9154",title:"Spinal Deformities in Adolescents, Adults and Older Adults",subtitle:null,isOpenForSubmission:!1,hash:"313f1dffa803b60a14ff1e6966e93d91",slug:"spinal-deformities-in-adolescents-adults-and-older-adults",bookSignature:"Josette Bettany-Saltikov and Gokulakannan Kandasamy",coverURL:"https://cdn.intechopen.com/books/images_new/9154.jpg",editors:[{id:"94802",title:"Dr.",name:"Josette",middleName:null,surname:"Bettany-Saltikov",slug:"josette-bettany-saltikov",fullName:"Josette Bettany-Saltikov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10405",title:"River Basin Management",subtitle:"Sustainability Issues and Planning Strategies",isOpenForSubmission:!1,hash:"5e5ddd0f2eda107ce19c4c06a55a8351",slug:"river-basin-management-sustainability-issues-and-planning-strategies",bookSignature:"José Simão Antunes Do Carmo",coverURL:"https://cdn.intechopen.com/books/images_new/10405.jpg",editors:[{id:"67904",title:"Prof.",name:"José Simão",middleName:null,surname:"Antunes Do Carmo",slug:"jose-simao-antunes-do-carmo",fullName:"José Simão Antunes Do Carmo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7030",title:"Satellite Systems",subtitle:"Design, Modeling, Simulation and Analysis",isOpenForSubmission:!1,hash:"b9db6d2645ef248ceb1b33ea75f38e88",slug:"satellite-systems-design-modeling-simulation-and-analysis",bookSignature:"Tien Nguyen",coverURL:"https://cdn.intechopen.com/books/images_new/7030.jpg",editors:[{id:"210657",title:"Dr.",name:"Tien M.",middleName:"Manh",surname:"Nguyen",slug:"tien-m.-nguyen",fullName:"Tien M. Nguyen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8472",title:"Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health",subtitle:null,isOpenForSubmission:!1,hash:"8855452919b8495810ef8e88641feb20",slug:"bioactive-compounds-in-nutraceutical-and-functional-food-for-good-human-health",bookSignature:"Kavita Sharma, Kanchan Mishra, Kula Kamal Senapati and Corina Danciu",coverURL:"https://cdn.intechopen.com/books/images_new/8472.jpg",editors:[{id:"197731",title:"Dr.",name:"Kavita",middleName:null,surname:"Sharma",slug:"kavita-sharma",fullName:"Kavita Sharma"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10201",title:"Post-Transition Metals",subtitle:null,isOpenForSubmission:!1,hash:"cc7f53ff5269916e3ce29f65a51a87ae",slug:"post-transition-metals",bookSignature:"Mohammed Muzibur Rahman, Abdullah Mohammed Asiri, Anish Khan, Inamuddin and Thamer Tabbakh",coverURL:"https://cdn.intechopen.com/books/images_new/10201.jpg",editors:[{id:"24438",title:"Prof.",name:"Mohammed Muzibur",middleName:null,surname:"Rahman",slug:"mohammed-muzibur-rahman",fullName:"Mohammed Muzibur Rahman"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10413",title:"A Collection of Papers on Chaos Theory and Its Applications",subtitle:null,isOpenForSubmission:!1,hash:"900b71b164948830fec3d6254b7881f7",slug:"a-collection-of-papers-on-chaos-theory-and-its-applications",bookSignature:"Paul Bracken and Dimo I. Uzunov",coverURL:"https://cdn.intechopen.com/books/images_new/10413.jpg",editors:[{id:"92883",title:"Prof.",name:"Paul",middleName:null,surname:"Bracken",slug:"paul-bracken",fullName:"Paul Bracken"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9515",title:"Update in Geriatrics",subtitle:null,isOpenForSubmission:!1,hash:"913e16c0ae977474b283bbd4269564c8",slug:"update-in-geriatrics",bookSignature:"Somchai Amornyotin",coverURL:"https://cdn.intechopen.com/books/images_new/9515.jpg",editors:[{id:"185484",title:"Prof.",name:"Somchai",middleName:null,surname:"Amornyotin",slug:"somchai-amornyotin",fullName:"Somchai Amornyotin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8148",title:"Investment Strategies in Emerging New Trends in Finance",subtitle:null,isOpenForSubmission:!1,hash:"3b714d96a68d2acdfbd7b50aba6504ca",slug:"investment-strategies-in-emerging-new-trends-in-finance",bookSignature:"Reza Gharoie Ahangar and Asma Salman",coverURL:"https://cdn.intechopen.com/books/images_new/8148.jpg",editors:[{id:"91081",title:"Dr.",name:"Reza",middleName:null,surname:"Gharoie Ahangar",slug:"reza-gharoie-ahangar",fullName:"Reza Gharoie Ahangar"}],equalEditorOne:{id:"206443",title:"Prof.",name:"Asma",middleName:null,surname:"Salman",slug:"asma-salman",fullName:"Asma Salman",profilePictureURL:"https://mts.intechopen.com/storage/users/206443/images/system/206443.png",biography:"Professor Asma Salman is a blockchain developer and Professor of Finance at the American University in the Emirates, UAE. An Honorary Global Advisor at the Global Academy of Finance and Management, USA, she completed her MBA in Finance and Accounting and earned a Ph.D. in Finance from an AACSB member, AMBA accredited, School of Management at Harbin Institute of Technology, China. Her research credentials include a one-year residency at the Brunel Business School, Brunel University, UK. Prof. Salman also served as the Dubai Cohort supervisor for DBA students under the Nottingham Business School, UK, for seven years and is currently a Ph.D. supervisor at the University of Northampton, UK, where she is a visiting fellow. She also served on the Board of Etihad Airlines during 2019–2020. One of her recent articles on “Bitcoin and Blockchain” gained wide visibility and she is an active speaker on Fintech, blockchain, and crypto events around the GCC. She holds various professional certifications including Chartered Fintech Professional (USA), Certified Financial Manager (USA), Women in Leadership and Management in Higher Education, (UK), and Taxation GCC VAT Compliance, (UK). She recently won an award for “Blockchain Trainer of the Year” from Berkeley Middle East. Other recognitions include the Women Leadership Impact Award by H.E First Lady of Armenia, Research Excellence Award, and the Global Inspirational Women Leadership Award by H.H Sheikh Juma Bin Maktoum Juma Al Maktoum.",institutionString:"American University in the Emirates",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"American University in the Emirates",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5334},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9893",title:"Automation and Control",subtitle:null,isOpenForSubmission:!1,hash:"09ba24f6ac88af7f0aaff3029714ae48",slug:"automation-and-control",bookSignature:"Constantin Voloşencu, Serdar Küçük, José Guerrero and Oscar Valero",coverURL:"https://cdn.intechopen.com/books/images_new/9893.jpg",editors:[{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7016",title:"Cardiovascular Risk Factors in Pathology",subtitle:null,isOpenForSubmission:!1,hash:"7937d2c640c7515de372282c72ee5635",slug:"cardiovascular-risk-factors-in-pathology",bookSignature:"Alaeddin Abukabda, Maria Suciu and Minodora Andor",coverURL:"https://cdn.intechopen.com/books/images_new/7016.jpg",editors:[{id:"307873",title:"Ph.D.",name:"Alaeddin",middleName:null,surname:"Abukabda",slug:"alaeddin-abukabda",fullName:"Alaeddin Abukabda"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9873",title:"Strategies of Sustainable Solid Waste Management",subtitle:null,isOpenForSubmission:!1,hash:"59b5ceeeedaf7449a30629923569388c",slug:"strategies-of-sustainable-solid-waste-management",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/9873.jpg",editors:[{id:"144691",title:"Prof.",name:"Hosam M.",middleName:"M.",surname:"Saleh",slug:"hosam-m.-saleh",fullName:"Hosam M. Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9154",title:"Spinal Deformities in Adolescents, Adults and Older Adults",subtitle:null,isOpenForSubmission:!1,hash:"313f1dffa803b60a14ff1e6966e93d91",slug:"spinal-deformities-in-adolescents-adults-and-older-adults",bookSignature:"Josette Bettany-Saltikov and Gokulakannan Kandasamy",coverURL:"https://cdn.intechopen.com/books/images_new/9154.jpg",editors:[{id:"94802",title:"Dr.",name:"Josette",middleName:null,surname:"Bettany-Saltikov",slug:"josette-bettany-saltikov",fullName:"Josette Bettany-Saltikov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10405",title:"River Basin Management",subtitle:"Sustainability Issues and Planning Strategies",isOpenForSubmission:!1,hash:"5e5ddd0f2eda107ce19c4c06a55a8351",slug:"river-basin-management-sustainability-issues-and-planning-strategies",bookSignature:"José Simão Antunes Do Carmo",coverURL:"https://cdn.intechopen.com/books/images_new/10405.jpg",editors:[{id:"67904",title:"Prof.",name:"José Simão",middleName:null,surname:"Antunes Do Carmo",slug:"jose-simao-antunes-do-carmo",fullName:"José Simão Antunes Do Carmo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7030",title:"Satellite Systems",subtitle:"Design, Modeling, Simulation and Analysis",isOpenForSubmission:!1,hash:"b9db6d2645ef248ceb1b33ea75f38e88",slug:"satellite-systems-design-modeling-simulation-and-analysis",bookSignature:"Tien Nguyen",coverURL:"https://cdn.intechopen.com/books/images_new/7030.jpg",editors:[{id:"210657",title:"Dr.",name:"Tien M.",middleName:"Manh",surname:"Nguyen",slug:"tien-m.-nguyen",fullName:"Tien M. Nguyen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8472",title:"Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health",subtitle:null,isOpenForSubmission:!1,hash:"8855452919b8495810ef8e88641feb20",slug:"bioactive-compounds-in-nutraceutical-and-functional-food-for-good-human-health",bookSignature:"Kavita Sharma, Kanchan Mishra, Kula Kamal Senapati and Corina Danciu",coverURL:"https://cdn.intechopen.com/books/images_new/8472.jpg",editors:[{id:"197731",title:"Dr.",name:"Kavita",middleName:null,surname:"Sharma",slug:"kavita-sharma",fullName:"Kavita Sharma"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10201",title:"Post-Transition Metals",subtitle:null,isOpenForSubmission:!1,hash:"cc7f53ff5269916e3ce29f65a51a87ae",slug:"post-transition-metals",bookSignature:"Mohammed Muzibur Rahman, Abdullah Mohammed Asiri, Anish Khan, Inamuddin and Thamer Tabbakh",coverURL:"https://cdn.intechopen.com/books/images_new/10201.jpg",editors:[{id:"24438",title:"Prof.",name:"Mohammed Muzibur",middleName:null,surname:"Rahman",slug:"mohammed-muzibur-rahman",fullName:"Mohammed Muzibur Rahman"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10413",title:"A Collection of Papers on Chaos Theory and Its Applications",subtitle:null,isOpenForSubmission:!1,hash:"900b71b164948830fec3d6254b7881f7",slug:"a-collection-of-papers-on-chaos-theory-and-its-applications",bookSignature:"Paul Bracken and Dimo I. Uzunov",coverURL:"https://cdn.intechopen.com/books/images_new/10413.jpg",editors:[{id:"92883",title:"Prof.",name:"Paul",middleName:null,surname:"Bracken",slug:"paul-bracken",fullName:"Paul Bracken"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9515",title:"Update in Geriatrics",subtitle:null,isOpenForSubmission:!1,hash:"913e16c0ae977474b283bbd4269564c8",slug:"update-in-geriatrics",bookSignature:"Somchai Amornyotin",coverURL:"https://cdn.intechopen.com/books/images_new/9515.jpg",editors:[{id:"185484",title:"Prof.",name:"Somchai",middleName:null,surname:"Amornyotin",slug:"somchai-amornyotin",fullName:"Somchai Amornyotin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9559",title:"Teamwork in Healthcare",subtitle:null,isOpenForSubmission:!1,hash:"0053c2ff8d9ec4cc4aab82acea46a41e",slug:"teamwork-in-healthcare",bookSignature:"Michael S. Firstenberg and Stanislaw P. Stawicki",coverURL:"https://cdn.intechopen.com/books/images_new/9559.jpg",editedByType:"Edited by",editors:[{id:"64343",title:null,name:"Michael S.",middleName:null,surname:"Firstenberg",slug:"michael-s.-firstenberg",fullName:"Michael S. Firstenberg"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7016",title:"Cardiovascular Risk Factors in Pathology",subtitle:null,isOpenForSubmission:!1,hash:"7937d2c640c7515de372282c72ee5635",slug:"cardiovascular-risk-factors-in-pathology",bookSignature:"Alaeddin Abukabda, Maria Suciu and Minodora Andor",coverURL:"https://cdn.intechopen.com/books/images_new/7016.jpg",editedByType:"Edited by",editors:[{id:"307873",title:"Ph.D.",name:"Alaeddin",middleName:null,surname:"Abukabda",slug:"alaeddin-abukabda",fullName:"Alaeddin Abukabda"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9873",title:"Strategies of Sustainable Solid Waste Management",subtitle:null,isOpenForSubmission:!1,hash:"59b5ceeeedaf7449a30629923569388c",slug:"strategies-of-sustainable-solid-waste-management",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/9873.jpg",editedByType:"Edited by",editors:[{id:"144691",title:"Prof.",name:"Hosam M.",middleName:"M.",surname:"Saleh",slug:"hosam-m.-saleh",fullName:"Hosam M. Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9893",title:"Automation and Control",subtitle:null,isOpenForSubmission:!1,hash:"09ba24f6ac88af7f0aaff3029714ae48",slug:"automation-and-control",bookSignature:"Constantin Voloşencu, Serdar Küçük, José Guerrero and Oscar Valero",coverURL:"https://cdn.intechopen.com/books/images_new/9893.jpg",editedByType:"Edited by",editors:[{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10405",title:"River Basin Management",subtitle:"Sustainability Issues and Planning Strategies",isOpenForSubmission:!1,hash:"5e5ddd0f2eda107ce19c4c06a55a8351",slug:"river-basin-management-sustainability-issues-and-planning-strategies",bookSignature:"José Simão Antunes Do Carmo",coverURL:"https://cdn.intechopen.com/books/images_new/10405.jpg",editedByType:"Edited by",editors:[{id:"67904",title:"Prof.",name:"José Simão",middleName:null,surname:"Antunes Do Carmo",slug:"jose-simao-antunes-do-carmo",fullName:"José Simão Antunes Do Carmo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9515",title:"Update in Geriatrics",subtitle:null,isOpenForSubmission:!1,hash:"913e16c0ae977474b283bbd4269564c8",slug:"update-in-geriatrics",bookSignature:"Somchai Amornyotin",coverURL:"https://cdn.intechopen.com/books/images_new/9515.jpg",editedByType:"Edited by",editors:[{id:"185484",title:"Prof.",name:"Somchai",middleName:null,surname:"Amornyotin",slug:"somchai-amornyotin",fullName:"Somchai Amornyotin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9021",title:"Novel Perspectives of Stem Cell Manufacturing and Therapies",subtitle:null,isOpenForSubmission:!1,hash:"522c6db871783d2a11c17b83f1fd4e18",slug:"novel-perspectives-of-stem-cell-manufacturing-and-therapies",bookSignature:"Diana Kitala and Ana Colette Maurício",coverURL:"https://cdn.intechopen.com/books/images_new/9021.jpg",editedByType:"Edited by",editors:[{id:"203598",title:"Ph.D.",name:"Diana",middleName:null,surname:"Kitala",slug:"diana-kitala",fullName:"Diana Kitala"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7030",title:"Satellite Systems",subtitle:"Design, Modeling, Simulation and Analysis",isOpenForSubmission:!1,hash:"b9db6d2645ef248ceb1b33ea75f38e88",slug:"satellite-systems-design-modeling-simulation-and-analysis",bookSignature:"Tien Nguyen",coverURL:"https://cdn.intechopen.com/books/images_new/7030.jpg",editedByType:"Edited by",editors:[{id:"210657",title:"Dr.",name:"Tien M.",middleName:"Manh",surname:"Nguyen",slug:"tien-m.-nguyen",fullName:"Tien M. Nguyen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10413",title:"A Collection of Papers on Chaos Theory and Its Applications",subtitle:null,isOpenForSubmission:!1,hash:"900b71b164948830fec3d6254b7881f7",slug:"a-collection-of-papers-on-chaos-theory-and-its-applications",bookSignature:"Paul Bracken and Dimo I. Uzunov",coverURL:"https://cdn.intechopen.com/books/images_new/10413.jpg",editedByType:"Edited by",editors:[{id:"92883",title:"Prof.",name:"Paul",middleName:null,surname:"Bracken",slug:"paul-bracken",fullName:"Paul Bracken"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9154",title:"Spinal Deformities in Adolescents, Adults and Older Adults",subtitle:null,isOpenForSubmission:!1,hash:"313f1dffa803b60a14ff1e6966e93d91",slug:"spinal-deformities-in-adolescents-adults-and-older-adults",bookSignature:"Josette Bettany-Saltikov and Gokulakannan Kandasamy",coverURL:"https://cdn.intechopen.com/books/images_new/9154.jpg",editedByType:"Edited by",editors:[{id:"94802",title:"Dr.",name:"Josette",middleName:null,surname:"Bettany-Saltikov",slug:"josette-bettany-saltikov",fullName:"Josette Bettany-Saltikov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"733",title:"Wireless Communication Network",slug:"engineering-control-engineering-wireless-communication-network",parent:{title:"Control Engineering",slug:"engineering-control-engineering"},numberOfBooks:3,numberOfAuthorsAndEditors:80,numberOfWosCitations:117,numberOfCrossrefCitations:84,numberOfDimensionsCitations:179,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"engineering-control-engineering-wireless-communication-network",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"2387",title:"New Approach of Indoor and Outdoor Localization Systems",subtitle:null,isOpenForSubmission:!1,hash:"0ca0243d04d5f4e7c6d9e9c54d6cc6f5",slug:"new-approach-of-indoor-and-outdoor-localization-systems",bookSignature:"Fouzia Boukour Elbahhar and Atika Rivenq",coverURL:"https://cdn.intechopen.com/books/images_new/2387.jpg",editedByType:"Edited by",editors:[{id:"140822",title:"Dr.",name:"Fouzia",middleName:null,surname:"Elbahhar",slug:"fouzia-elbahhar",fullName:"Fouzia Elbahhar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"393",title:"Adaptive Filtering Applications",subtitle:null,isOpenForSubmission:!1,hash:"fcca6dde43a408a5cc07096108c37ece",slug:"adaptive-filtering-applications",bookSignature:"Lino Garcia",coverURL:"https://cdn.intechopen.com/books/images_new/393.jpg",editedByType:"Edited by",editors:[{id:"682",title:"Dr.",name:"Lino",middleName:null,surname:"Garcia Morales",slug:"lino-garcia-morales",fullName:"Lino Garcia Morales"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3743",title:"Fault Detection",subtitle:null,isOpenForSubmission:!1,hash:"72846863e133fd8ef84ab2379a43405d",slug:"fault-detection",bookSignature:"Wei Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/3743.jpg",editedByType:"Edited by",editors:[{id:"3605",title:"Dr.",name:"Wei",middleName:null,surname:"Zhang",slug:"wei-zhang",fullName:"Wei Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:3,mostCitedChapters:[{id:"10363",doi:"10.5772/9072",title:"Mechanical Fault Detection in Induction Motor Drives through Stator Current Monitoring - Theory and Application Examples",slug:"mechanical-fault-detection-in-induction-motor-drives-through-stator-current-monitoring-theory-and-ap",totalDownloads:5933,totalCrossrefCites:10,totalDimensionsCites:15,book:{slug:"fault-detection",title:"Fault Detection",fullTitle:"Fault Detection"},signatures:"Martin Blodt, Pierre Granjon, Bertrand Raison and Jeremi Regnier",authors:null},{id:"39780",doi:"10.5772/50448",title:"GNSS in Precision Agricultural Operations",slug:"gnss-in-precision-agricultural-operations",totalDownloads:3734,totalCrossrefCites:8,totalDimensionsCites:14,book:{slug:"new-approach-of-indoor-and-outdoor-localization-systems",title:"New Approach of Indoor and Outdoor Localization Systems",fullTitle:"New Approach of Indoor and Outdoor Localization Systems"},signatures:"Manuel Perez-Ruiz and Shrini K. Upadhyaya",authors:[{id:"142870",title:"Prof.",name:"Manuel",middleName:null,surname:"Perez-Ruiz",slug:"manuel-perez-ruiz",fullName:"Manuel Perez-Ruiz"}]},{id:"16119",doi:"10.5772/17219",title:"Noise Removal from EEG Signals in Polisomnographic Records Applying Adaptive Filters in Cascade",slug:"noise-removal-from-eeg-signals-in-polisomnographic-records-applying-adaptive-filters-in-cascade",totalDownloads:5988,totalCrossrefCites:3,totalDimensionsCites:13,book:{slug:"adaptive-filtering-applications",title:"Adaptive Filtering Applications",fullTitle:"Adaptive Filtering Applications"},signatures:"M. Agustina Garces Correa and Eric Laciar Leber",authors:[{id:"27636",title:"Mrs",name:"Maria Agustina",middleName:null,surname:"Garces Correa",slug:"maria-agustina-garces-correa",fullName:"Maria Agustina Garces Correa"},{id:"35003",title:"Prof.",name:"Eric",middleName:null,surname:"Laciar",slug:"eric-laciar",fullName:"Eric Laciar"}]}],mostDownloadedChaptersLast30Days:[{id:"16112",title:"Applications of Adaptive Filtering",slug:"applications-of-adaptive-filtering",totalDownloads:10690,totalCrossrefCites:2,totalDimensionsCites:8,book:{slug:"adaptive-filtering-applications",title:"Adaptive Filtering Applications",fullTitle:"Adaptive Filtering Applications"},signatures:"J. Gerardo Avalos, Juan C. Sanchez and Jose Velazquez",authors:[{id:"26570",title:"MSc",name:"Juan",middleName:"Gerardo",surname:"Avalos",slug:"juan-avalos",fullName:"Juan Avalos"},{id:"67182",title:"Dr.",name:"Juan",middleName:null,surname:"Sanchez",slug:"juan-sanchez",fullName:"Juan Sanchez"},{id:"67184",title:"Dr.",name:"Jose",middleName:null,surname:"Velazquez",slug:"jose-velazquez",fullName:"Jose Velazquez"}]},{id:"39779",title:"Inertial Navigation Systems and Its Practical Applications",slug:"inertial-navigation-systems-and-its-practical-applications",totalDownloads:3678,totalCrossrefCites:5,totalDimensionsCites:8,book:{slug:"new-approach-of-indoor-and-outdoor-localization-systems",title:"New Approach of Indoor and Outdoor Localization Systems",fullTitle:"New Approach of Indoor and Outdoor Localization Systems"},signatures:"Aleksander Nawrat, Karol Jędrasiak, Krzysztof Daniec and Roman Koteras",authors:[{id:"142216",title:"Prof.",name:"Aleksander",middleName:null,surname:"Nawrat",slug:"aleksander-nawrat",fullName:"Aleksander Nawrat"},{id:"162962",title:"MSc.",name:"Karol",middleName:null,surname:"Jędrasiak",slug:"karol-jedrasiak",fullName:"Karol Jędrasiak"},{id:"162963",title:"MSc.",name:"Krzysztof",middleName:null,surname:"Daniec",slug:"krzysztof-daniec",fullName:"Krzysztof Daniec"}]},{id:"39778",title:"GPS and the One-Way Speed of Light",slug:"gps-and-the-one-way-speed-of-light",totalDownloads:2802,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"new-approach-of-indoor-and-outdoor-localization-systems",title:"New Approach of Indoor and Outdoor Localization Systems",fullTitle:"New Approach of Indoor and Outdoor Localization Systems"},signatures:"Stephan J.G. Gift",authors:[{id:"141106",title:"Prof.",name:"Stephan",middleName:null,surname:"Gift",slug:"stephan-gift",fullName:"Stephan Gift"}]},{id:"10367",title:"Fault Detection in Crypto-Devices",slug:"fault-detection-in-crypto-devices",totalDownloads:2273,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"fault-detection",title:"Fault Detection",fullTitle:"Fault Detection"},signatures:"K. Bousselam, G. Di Natale, M.-L. Flottes and B. Rouzeyre",authors:null},{id:"16116",title:"Adaptive Noise Removal of ECG Signal Based On Ensemble Empirical Mode Decomposition",slug:"adaptive-noise-removal-of-ecg-signal-based-on-ensemble-empirical-mode-decomposition",totalDownloads:3223,totalCrossrefCites:3,totalDimensionsCites:5,book:{slug:"adaptive-filtering-applications",title:"Adaptive Filtering Applications",fullTitle:"Adaptive Filtering Applications"},signatures:"Zhao Zhidong, Luo Yi and Lu Qing",authors:[{id:"24493",title:"Dr.",name:"Zhidong",middleName:null,surname:"Zhao",slug:"zhidong-zhao",fullName:"Zhidong Zhao"},{id:"70484",title:"Mr.",name:"Yi",middleName:null,surname:"Luo",slug:"yi-luo",fullName:"Yi Luo"},{id:"70489",title:"Ms.",name:"Qing",middleName:null,surname:"Lu",slug:"qing-lu",fullName:"Qing Lu"}]},{id:"16123",title:"An Introduction to ANFIS Based Channel Equalizers for Mobile Cellular Channels",slug:"an-introduction-to-anfis-based-channel-equalizers-for-mobile-cellular-channels",totalDownloads:4129,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"adaptive-filtering-applications",title:"Adaptive Filtering Applications",fullTitle:"Adaptive Filtering Applications"},signatures:"K. C. Raveendranathan",authors:[{id:"24518",title:"Prof.",name:"Dr. Raveendranathan",middleName:null,surname:"K C",slug:"dr.-raveendranathan-k-c",fullName:"Dr. Raveendranathan K C"}]},{id:"16115",title:"Perceptual Echo Control and Delay Estimation",slug:"perceptual-echo-control-and-delay-estimation",totalDownloads:2591,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"adaptive-filtering-applications",title:"Adaptive Filtering Applications",fullTitle:"Adaptive Filtering Applications"},signatures:"Kirill Sakhnov, Ekaterina Verteletskaya and Boris Simak",authors:[{id:"25956",title:"MSc",name:"Kirill",middleName:null,surname:"Sakhnov",slug:"kirill-sakhnov",fullName:"Kirill Sakhnov"},{id:"78922",title:"MSc.",name:"Ekaterina",middleName:null,surname:"Verteletskaya",slug:"ekaterina-verteletskaya",fullName:"Ekaterina Verteletskaya"},{id:"78923",title:"Prof.",name:"Boris",middleName:null,surname:"Simak",slug:"boris-simak",fullName:"Boris Simak"}]},{id:"16118",title:"Adaptive Filtering by Non-Invasive Vital Signals Monitoring and Diseases Diagnosis",slug:"adaptive-filtering-by-non-invasive-vital-signals-monitoring-and-diseases-diagnosis",totalDownloads:5349,totalCrossrefCites:3,totalDimensionsCites:5,book:{slug:"adaptive-filtering-applications",title:"Adaptive Filtering Applications",fullTitle:"Adaptive Filtering Applications"},signatures:"Omar Abdallah and Armin Bolz",authors:[{id:"26443",title:"Prof.",name:"Omar",middleName:null,surname:"Abdallah",slug:"omar-abdallah",fullName:"Omar Abdallah"},{id:"80048",title:"Prof.",name:"Armin",middleName:null,surname:"Bolz",slug:"armin-bolz",fullName:"Armin Bolz"}]},{id:"16121",title:"A LEO Nano-Satellite Mission for the Detection of Lightning VHF Sferics",slug:"a-leo-nano-satellite-mission-for-the-detection-of-lightning-vhf-sferics",totalDownloads:2248,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"adaptive-filtering-applications",title:"Adaptive Filtering Applications",fullTitle:"Adaptive Filtering Applications"},signatures:"Ghulam Jaffer, Hans U. Eichelberger, Konrad Schwingenschuh and Otto Koudelka",authors:[{id:"25991",title:"Dr.",name:"Ghulam",middleName:null,surname:"Jaffer",slug:"ghulam-jaffer",fullName:"Ghulam Jaffer"},{id:"35961",title:"Prof.",name:"Otto",middleName:null,surname:"Koudelka",slug:"otto-koudelka",fullName:"Otto Koudelka"},{id:"43099",title:"Mr",name:"Hans",middleName:null,surname:"Eichelberger",slug:"hans-eichelberger",fullName:"Hans Eichelberger"},{id:"43100",title:"Dr.",name:"Konrad",middleName:null,surname:"Schwingenschuh",slug:"konrad-schwingenschuh",fullName:"Konrad Schwingenschuh"}]},{id:"39776",title:"Activity-Artifact Flow of GPS/INS Integration for Positioning Error De-Correlation",slug:"activity-artifact-flow-of-gps-ins-integration-for-positioning-error-de-correlation",totalDownloads:1636,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"new-approach-of-indoor-and-outdoor-localization-systems",title:"New Approach of Indoor and Outdoor Localization Systems",fullTitle:"New Approach of Indoor and Outdoor Localization Systems"},signatures:"Xiaoying Kong, Li Liu and Heung-Gyoon Ryu",authors:[{id:"124291",title:"Dr.",name:"Xiaoying",middleName:null,surname:"Kong",slug:"xiaoying-kong",fullName:"Xiaoying Kong"},{id:"150933",title:"Dr.",name:"Li",middleName:null,surname:"Liu",slug:"li-liu",fullName:"Li Liu"},{id:"150934",title:"Prof.",name:"Heung-Gyoon",middleName:null,surname:"Ryu",slug:"heung-gyoon-ryu",fullName:"Heung-Gyoon Ryu"}]}],onlineFirstChaptersFilter:{topicSlug:"engineering-control-engineering-wireless-communication-network",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/53743/choichiro-tase",hash:"",query:{},params:{id:"53743",slug:"choichiro-tase"},fullPath:"/profiles/53743/choichiro-tase",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()